Filtered By:
Condition: Diabetes Type 2

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 3594 results found since Jan 2013.

Ischemic Stroke Management: Posthospitalization and Transition of Care
Am Fam Physician. 2023 Jul;108(1):70-77.ABSTRACTIschemic stroke is a major cause of morbidity and mortality worldwide. Ischemic stroke and transient ischemic attack exist on a continuum of the same disease process. Ischemic stroke is common, and more than 85% of stroke risk is attributed to modifiable risk factors. The initial management of acute stroke is usually performed in the emergency department and hospital settings. Family physicians have a key role in follow-up, ensuring that a complete diagnostic evaluation has been performed, addressing modifiable risk factors, facilitating rehabilitation, and managing chronic s...
Source: American Family Physician - July 13, 2023 Category: Primary Care Authors: Scott T Larson Brigit E Ray Jason Wilbur Source Type: research

The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride.
Abstract Type 2 diabetes is a strong risk factor for stroke. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes. The aim of this study was to determine the potential antistroke efficacy of linagliptin in type 2 diabetic mice. To understand whether efficacy was mediated by glycemia regulation, a comparison with the sulfonylurea glimepiride was done. To determine whether linagliptin-mediated efficacy was dependent on a diabetic background, experiments in nondiabetic mice were performed. Type 2 diabetes was induced by feeding the mice a high-fat diet for 32 weeks. Mice w...
Source: Diabetes - December 17, 2012 Category: Endocrinology Authors: Darsalia V, Ortsäter H, Olverling A, Darlöf E, Wolbert P, Nyström T, Klein T, Sjöholm A, Patrone C Tags: Diabetes Source Type: research

Risk of Ischemic Stroke After an Acute Myocardial Infarction in Patients With Diabetes Mellitus Original Articles
Conclusions— Ischemic stroke is a fairly common complication after an AMI in patients with diabetes mellitus, but the risk of stroke has decreased during recent years. The increased use of evidence-based therapies contributes importantly to this risk reduction, but there is still room for improvement.
Source: Circulation: Cardiovascular Quality and Outcomes - January 21, 2014 Category: Cardiology Authors: Jakobsson, S., Bergstrom, L., Bjorklund, F., Jernberg, T., Soderstrom, L., Mooe, T. Tags: Secondary prevention, Type 1 diabetes, Type 2 diabetes, Acute myocardial infarction, Acute Cerebral Infarction Original Articles Source Type: research

Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
In conclusion, we found no correlation between acute neuroprotection (occurring in both T2D and normal mice) and increased NSC proliferation (occurring only in T2D mice). However, our results show that linagliptin evokes a differential response on NSC proliferation after stroke in normal and T2D mice suggesting that DPP-4 inhibition effect in the CNS might go beyond the well known increase of GLP-1. PMID: 24821550 [PubMed - as supplied by publisher]
Source: Regulatory Peptides - May 9, 2014 Category: Biochemistry Authors: Darsalia V, Olverling A, Larsson M, Mansouri S, Nathanson D, Nyström T, Klein T, Sjöholm A, Patrone C Tags: Regul Pept Source Type: research

Prolonged P wave duration predicts stroke mortality among type 2 diabetic patients with prevalent non-major macrovascular disease
Conclusions: As an easily measurable factor P wave duration merits further studies with higher number of patients to evaluate its importance in the estimation of stroke risk in type 2 diabetic patients with PNMMVD.
Source: BMC Cardiovascular Disorders - November 25, 2014 Category: Cardiology Authors: Teemu VepsäläinenMarkku LaaksoSeppo LehtoAuni JuutilainenJuhani AiraksinenTapani Rönnemaa Source Type: research

Potentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus
In conclusion, experimental studies show promising results of incretin‐based therapies at improving the outcome of Alzheimer's disease and stroke through glucose‐independent pleiotropic effects on the brain. If these findings would indeed be confirmed in large clinical randomized controlled trials, this would have substantial impact. This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - August 24, 2015 Category: Endocrinology Authors: Onno. N. Groeneveld, L. Jaap. Kappelle, Geert Jan Biessels Tags: Review Source Type: research

Body mass index in early and middle adult life: prospective associations with myocardial infarction, stroke and diabetes over a 30-year period: the British Regional Heart Study
Conclusions Higher BMI at 21 years of age is associated with later diabetes incidence but not MI or stroke, while higher BMI in middle age is strongly associated with all outcomes. Early obesity prevention may reduce later type 2 diabetes risk, more than MI and stroke.
Source: BMJ Open - September 15, 2015 Category: Journals (General) Authors: Owen, C. G., Kapetanakis, V. V., Rudnicka, A. R., Wathern, A. K., Lennon, L., Papacosta, O., Cook, D. G., Wannamethee, S. G., Whincup, P. H. Tags: Open access, Cardiovascular medicine, Epidemiology, Public health, Diabetes and Endocrinology Research Source Type: research

Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke
In conclusion, prior treatment with dipeptidyl peptidase 4 inhibitors in patients with acute ischaemic stroke appears to be associated with better functional outcome and lower mortality risk.
Source: Diabetes and Vascular Disease Research - October 22, 2015 Category: Endocrinology Authors: Tziomalos, K., Bouziana, S. D., Spanou, M., Kostaki, S., Papadopoulou, M., Giampatzis, V., Dourliou, V., Kostourou, D.-T., Savopoulos, C., Hatzitolios, A. I. Tags: Brief Reports Source Type: research

Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study
Conclusion: Our study supports the hypothesis that the risks of MACEs and two additional secondary outcomes in patients with diabetes who survived ischemic stroke did not differ according to ACEI versus ARB use.
Source: Journal of Hypertension - January 30, 2016 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research

Bone marrow stromal cells inhibits HMGB1-mediated inflammation after stroke in type 2 diabetic rats
Publication date: 2 June 2016 Source:Neuroscience, Volume 324 Author(s): J. Hu, B. Liu, Q. Zhao, P. Jin, F. Hua, Z. Zhang, Y. Liu, K. Zan, G. Cui, X. Ye High-mobility group box 1 (HMGB1), a ligand of receptor for advanced glycation endproducts (RAGE), functions as a proinflammatory factor. It is mainly involved in inflammatory activation and contributes to the initiation and progression of stroke. By using a model of transient middle cerebral artery occlusion (MCAo) in type 2 diabetic rats, we investigated the changes of pro-inflammation mediators, blood–brain barrier (BBB) leakage and functional outcome afte...
Source: Neuroscience - March 13, 2016 Category: Neuroscience Source Type: research

Gliptin‐mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon‐like peptide‐1 receptor
Gliptins are anti‐type 2 diabetes (T2D) drugs that regulate glycaemia by preventing endogenous glucagon‐like peptide‐1 (GLP‐1) degradation. Chronically administered gliptins before experimental stroke can also induce neuroprotection, and this effect is potentially relevant for reducing brain damage in patients with T2D and high risk of stroke. It is not known, however, whether acute gliptin treatment after stroke (mimicking a post‐hospitalization treatment) is neuroprotective or whether gliptin‐mediated neuroprotection occurs via GLP‐1‐receptor (GLP‐1R) activation. To answer these two questions, wild‐ty...
Source: Diabetes, Obesity and Metabolism - March 17, 2016 Category: Endocrinology Authors: V. Darsalia, M. Larsson, G. Lietzau, D. Nathanson, T. Nyström, T. Klein, C. Patrone Tags: RESEARCH LETTER Source Type: research

Bone marrow mesenchymal stem cells-conditioned medium enhances vascular remodeling after stroke in type 2 diabetic rats
In conclusion, enhanced expression of Ang1 and Tie2 in ischemic brain after BMSCs-CM treatment of stroke may contribute to the improved functional recovery after stroke in type 2 diabetic rats.
Source: Neuroscience Letters - February 26, 2017 Category: Neuroscience Source Type: research

Causal Associations of Adiposity and Body Fat Distribution with Coronary Heart Disease, Stroke Subtypes and Type 2 Diabetes: A Mendelian Randomization Analysis.
Conclusions -Both general and central adiposity have causal effects on CHD and T2D. Central adiposity may have a stronger effect on stroke risk. Future estimates of the burden of adiposity on health should include measures of central and general adiposity. PMID: 28500271 [PubMed - as supplied by publisher]
Source: Circulation - May 12, 2017 Category: Cardiology Authors: Dale C, Fatemifar G, Palmer T, White J, Prieto-Merino D, Zabaneh D, Engmann JEL, Shah T, Wong A, Warren HR, McLachlan S, Trompet S, Moldovan M, Morris RW, Sofat R, Kumari M, Hyppönen E, Jefferis BJ, Gaunt TR, Ben-Shlomo Y, Zhou A, Gentry-Maharaj A, Ryan Tags: Circulation Source Type: research

Atopic dermatitis and risk of hypertension, type 2 diabetes, myocardial infarction and stroke in a cross ‐sectional analysis from the Canadian Partnership for Tomorrow Project
ConclusionsWe did not find evidence of a positive association between AD and subsequent hypertension, T2D, MI or stroke; AD was inversely associated with these outcomes in our study. Given our findings and the conflicting literature, AD is likely not a major risk factor for cardiovascular disease.
Source: British Journal of Dermatology - September 10, 2017 Category: Dermatology Authors: A.M. Drucker, A.A. Qureshi, T.J.B. Dummer, L. Parker, W. ‐Q. Li Tags: Epidemiology Source Type: research